|
TTC17 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.17179640727272E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.34820000297876E-08 |
| Normal-vs-Stage2 |
9.64189999952403E-07 |
| Normal-vs-Stage3 |
1.16173737296776E-12 |
| Normal-vs-Stage4 |
3.05070002593055E-09 |
| Stage1-vs-Stage2 |
3.251600E-01 |
| Stage1-vs-Stage3 |
2.060500E-03 |
| Stage1-vs-Stage4 |
3.603500E-02 |
| Stage2-vs-Stage3 |
2.155800E-01 |
| Stage2-vs-Stage4 |
5.450400E-01 |
| Stage3-vs-Stage4 |
5.249400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.41160433237064E-11 |
| Normal-vs-AfricanAmerican |
3.803500E-03 |
| Normal-vs-Asian |
4.36590000000292E-05 |
| Caucasian-vs-AfricanAmerican |
2.643400E-01 |
| Caucasian-vs-Asian |
3.269800E-01 |
| AfricanAmerican-vs-Asian |
7.490400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.00899955057798E-10 |
| Normal-vs-Female |
1.27519994563841E-09 |
| Male-vs-Female |
1.621580E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.36839999518446E-08 |
| Normal-vs-Age(41-60Yrs) |
7.49259998489293E-09 |
| Normal-vs-Age(61-80Yrs) |
3.54509754885157E-11 |
| Normal-vs-Age(81-100Yrs) |
1.982270E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.326200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.333600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.236190E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.946620E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.531000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.124800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.235200E-04 |
| Classical-VS-Follicular |
6.853000E-01 |
| Classical-VS-Other |
6.034800E-01 |
| Classical-VS-Normal |
2.72069999862623E-09 |
| Tall-VS-Follicular |
1.096420E-02 |
| Tall-VS-Other |
4.467600E-01 |
| Tall-VS-Normal |
2.40849562516132E-11 |
| Follicular-VS-Other |
7.770000E-01 |
| Follicular-VS-Normal |
3.46039999998826E-06 |
| Other-VS-Normal |
1.029630E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.93620033736875E-10 |
| Normal-vs-N1 |
9.16529999672733E-08 |
| N0-vs-N1 |
6.537400E-01 |
|
|
